Navigation Links
GeneNews announces management changes to support commercialization of ColonSentry(TM)
Date:6/2/2008

TORONTO, June 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced management changes to support the commercialization of the Company's first product, ColonSentry(TM).

Effective May 31, 2008, Dr. K. Wayne Marshall has resigned as President and CEO to take on new duties as Chief Clinical Scientist for GeneNews. Dr. Marshall has also been appointed Vice Chair of the GeneNews Board of Directors. The Board has appointed a committee of three independent directors to manage the search for a new President and CEO. In the interim, Dr. Heiner Dreismann, an independent director of GeneNews and former President and CEO of Roche Molecular Diagnostics, will oversee the Company's business as Lead Director. Ms. Gailina Liew, formerly Senior Vice President, has also been appointed as acting Chief Operating Officer with responsibility for the operations of the Company.

"As GeneNews transitions into a commercial enterprise and prepares for the launch of ColonSentry, Wayne, the Board and I were in accordance that the timing was appropriate to transition leadership of the Company to a President and CEO with experience in the global commercialization of molecular diagnostics," said Mr. Rory Riggs, Chair of the Board of Directors. "In the interim, Dr. Dreismann's extensive experience and leadership at Roche Molecular Diagnostics will ensure that GeneNews is well prepared to enter the commercialization phase."

"We have worked hard to ensure that ColonSentry is the world's first blood-based test for colorectal cancer screening. I'm excited about the upcoming commercial launch of ColonSentry and committed to contributing to the future success of GeneNews in my new role as Chief Clinical Scientist and Vice Chair of the Board," added Dr. Marshall.

"I welcome the opportunity to play a leading role during this transition from development to commercialization," said Dr. Dreismann. "GeneNews has developed important technology that is expected to positively impact the molecular diagnostic field."

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... and ANN ARBOR, Mich. ... held biopharmaceutical company developing breakthrough immune modulatory medicines, announced ... of the Company,s lead therapeutic candidate, LYC-30937- E nteric ... often a debilitating skin disease that is estimated to ... the United States , with approximately 1.5 - ...
(Date:12/7/2016)... Boston, MA and Azusa, CA (PRWEB) , ... ... ... commercial provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, ... Brewing Company , will be the first to use Cambrian’s novel water-energy purchase ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA ... shopping cart. The new website has been designed to provide the best user-friendly ... customers to access detailed product information, read educational industry content as well as ...
(Date:12/7/2016)... Woods Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew ... 1966, Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in ... to shore, where the turtle became a minor sensation because no one could remember ever ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
Breaking Biology News(10 mins):